Our Team

A Biotechnology Company is Ultimately a bet on the Team.

We have carefully assembled a team of leading scientists, each bringing an average of 25+ years of experience in drug development. Their expertise spans neuroscience, receptor pharmacology, and precision therapeutics—particularly in the modulation of neurological pathways relevant to epilepsy.

With deep knowledge of receptor-targeted therapies and brain signaling, our team is dedicated to pioneering innovative treatments for drug-resistant seizures and transforming the landscape of epilepsy care.

Director, Chief Science Officer
Jan Torleif Pedersen

Jan Torleif Pedersen

Director, Chief Science Officer

Chief Medical Officer
Stephen D. Collins

Stephen D. Collins

Chief Medical Officer

Scientific Advisory Board

Leading experts in Epilepsy

Leading experts in Prader Willi Syndrome

Jennifer Miller

Director

Elizabeth Roof

Director

Tania Markovic

Director

Theresa V. Strong

Director

Leading experts in Neuropsychiatry

Michael P. Bogenschutz, MD

Director

Robert C. Malenka, MD, PhD

Director

Herbert Y. Meltzer

Director

Dr. Peter Hendricks Ph.D

Senior Advisor

Leadership

Ian McDonald

Chief Executive Officer, Director

Jan Torleif Pedersen

Director, Chief Science Officer

Stephen D. Collins

Chief Medical Officer

Alex Vasilkevich

Chief Operating Officer, Senior Scientific Officer

Ryan Cheung

Chief Financial Officer

Dr. John McCorvy Ph.D

Senior Advisor

Board of Directors

Ian McDonald

Chief Executive Officer, Director

Jan Torleif Pedersen

Director, Chief Science Officer

Dr. Steve J. Farr

Director

Jeremy Fryzuk

Director

Nils Bottler

Director
David Weiner, MD

David Weiner

Non-Executive Director